Search research articles
Contact Us
Filters
Showing results (981-990 of 1,482) with videos related to
Page
of 149
Sort By:
Human Gene Therapy
|
December 7, 2017
Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease
Edith L Pfister, Natalie DiNardo, Erica Mondo, et al.
Blood
|
March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
American Journal of Hematology
|
November 15, 2017
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Cancer
|
July 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
Elias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer
|
September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Elias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood
|
April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Haematologica
|
February 20, 2025
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Page
of 149
Search research articles
Search
Showing results (981-990 of 1,482) with videos related to
Sort By:
Page
of 149
Human Gene Therapy
|
December 7, 2017
Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease
Edith L Pfister, Natalie DiNardo, Erica Mondo, et al.
Blood
|
March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
American Journal of Hematology
|
November 15, 2017
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Cancer
|
July 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
Elias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer
|
September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Elias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood
|
April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Haematologica
|
February 20, 2025
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Page
of 149